Table of Contents
Ready to See Results?
From strategy through execution, Atlantic Health Strategies integrates compliance, operations, and growth into durable, measurable results. Let’s put our expertise to work for your organization.
The Aliya Headlines, and What They Actually Signal
Short answer: The Aliya Health Group headlines are not a one-company story. Founders and boards are watching the visible end of a 2018 to 2021 PE-backed buy-and-build cycle in addiction treatment resolve through layoffs, facility closures, and forced portfolio re-cuts. Operators who plan for contraction keep options. Operators who wait for the lender to force the conversation lose them.
Here is what the trade press has documented. In April 2026, Behavioral Health Business confirmed that Aliya Health Group has new leadership under CEO Frank Cid, laid off staff, and will shutter facilities, impacting about 80 employees. BHB identified two distinct events: a corporate layoff of roughly 40 people about a week after Cid stepped into the CEO role, and pending facility closures affecting another 37. One impacted employee described the cuts publicly as “a cost-cutting effort to ‘stop the bleeding.’”
Read the trades and it looks like one company’s hard year. Read it from operator advisory work and it looks like a pattern repeating across PE-backed multi-site behavioral health platforms since roughly 2022. The Private Equity Stakeholder Project tracked 1,049 PE-backed healthcare deals in 2024, with behavioral health identified as a noteworthy investment target alongside home health and disability services. A lot of those add-ons were tuck-ins underwritten on a payer mix and length-of-stay environment that no longer exists. Aliya is not unique. It is just visible.
What Actually Triggers the Turnaround Moment
When a board or a new CEO calls us, the trigger is almost never one thing. Boards and founders are usually reacting to three things stacked:
- Unit economics at two or three sites underwater for four to six quarters.
- Payer mix that shifted ten to fifteen points away from commercial toward Medicaid or self-pay without a corresponding cost structure adjustment.
- Platform expansion into a state or a level of care where licensing burden, staffing ratios, or local market saturation made the original pro forma fiction.
Add a covenant conversation with the lender and you get the 90-day review. The new CEO walks in, asks for site-level P&Ls, asks for census trends by referral source, asks which licenses are in good standing and which have open plans of correction. By day 30 they usually know which sites are keepers, which are fixable, and which are going to close. By day 60 they pressure-test those instincts against real feasibility data. By day 90 there is a board deck.
The contraction story is not confined to one operator. Jane Zhu, lead author of a widely cited JAMA Psychiatry study on PE penetration in behavioral health, told OHSU News, “At this point, there is no stone left unturned by private equity investors.” Operators who run the analysis annually, on their own footprint, while they still have options, do not end up as the cautionary tale in someone else’s article.
Feasibility Studies and Pro Formas as Decision Tools, Not Sales Documents
A feasibility study built to attract capital and a feasibility study built to decide whether to close a facility are different documents. The first tends to be optimistic about ramp, generous about payer mix, and quiet about competitive saturation. The second has to be honest or it is useless.
When AHS supports a portfolio review, the pro forma work looks at four things together:
- Site-level census against realistic referral capacity in the catchment.
- Current and projected reimbursement by payer with actual contracted rates, not blended assumptions.
- Staffing models that match the ASAM Criteria, 4th Edition acuity for the level of care being delivered.
- The fixed cost floor that does not move whether the site runs at 40 percent or 80 percent occupancy.
We also look at the licensure picture honestly. A facility with two open corrective action plans and a pending complaint survey is not the same risk profile as a clean site, and that has to show up in the numbers. In Arizona, for example, AHCCCS-contracted behavioral health providers work under incident reporting rules and sentinel event timelines set by the state. A site with an open incident trail looks very different on a defensible board deck than a site without one. The output is not a recommendation to close or keep. The output is a defensible basis for the board to make that call with eyes open.
The Licensure Mechanics of Closing or Consolidating
This is where operators get hurt. Closing a residential facility is not just turning off the lights. Depending on the state, operators have to work through:
- Notification requirements to the licensing agency, often with patient transition plans that must be documented and, in many cases, pre-approved.
- Accreditation withdrawal or suspension processes with The Joint Commission or CARF.
- DEA registration surrender if there is an OTP or controlled substance component, accomplished by written notice to the DEA and return of the original registration certificate.
- For OTPs, mandatory notification to SAMHSA’s Division of Pharmacologic Therapies via the online Form SMA-162 on the SAMHSA OTP Extranet, with a separate Form 162 required for each change.
- Medicaid and Medicare deactivation steps that have to be sequenced correctly to avoid recoupment exposure on the way out.
Consolidating two sites in the same state into one license is its own project. Some states treat it as a new license application. Some allow a modification. The difference can be six months on the timeline. Closing across states multiplies every one of these workstreams. Operators sometimes announce a closure publicly before the state agency has been notified in writing, which is a fast way to turn a business decision into an enforcement matter. The right sequence: model the decision, validate the licensure path with each state agency in writing, build the patient transition plan, then communicate.
Stress-Testing the Footprint Before Crisis
Operators who avoid the headline cycle are not smarter. They look earlier. An annual portfolio stress test, run independently of the budget process, catches the underwater site at quarter four of year one instead of quarter four of year three. That is the difference between a managed wind-down and a WARN notice.
The macro picture supports the urgency. The May 2024 JAMA Psychiatry study by Zhu, Greenberg, King, and Busch (OHSU, Wharton, and Yale) estimated the geographic penetration of PE-owned outpatient mental health and substance use disorder practices across the US. Researchers identified 642 mental health clinics and 1,152 clinics treating substance use disorders that had undergone PE acquisitions, accounting for 6.2 percent of all mental health facilities and 7.1 percent of addiction treatment facilities nationwide. In Colorado, Texas, and North Carolina, PE-owned practices accounted for roughly a quarter of all facilities providing mental health treatment. The platforms that came out of that expansion are at a decision point.
The enforcement environment is not getting friendlier either. On June 24, 2025, the FTC filed a complaint in the U.S. District Court for the District of Maryland naming Mercury Marketing, LLC; Behavioral Healthcare Group of America, LLC; JLux Consulting, LLC; Malibu Detox, LLC; Malibu Recovery Center, LLC; Aliya Health Group, LLC; Fennaside, LLC; JHEL Holding, LLC; and four individual defendants. FTC Bureau of Consumer Protection Director Christopher Mufarrige said the defendants “took advantage of consumers searching online for substance use disorder treatment services during one of the most difficult times in their lives.” For a comparable enforcement outcome, the FTC’s separate June 2025 case against Evoke Wellness settled for $1.9 million in penalties, with the company barred from similar misconduct. If you are a CEO or board member looking at a footprint that does not feel right, the work to fix it is finite and knowable. The longer you wait, the fewer levers you have.
Frequently asked questions
What does it mean when a PE-backed behavioral health platform announces layoffs and facility closures?
It almost always means three operational signals stacked: site-level unit economics underwater for multiple quarters, a payer mix shift away from commercial toward Medicaid or self-pay, and expansion into states or levels of care where the original pro forma was too optimistic. The April 2026 Behavioral Health Business reporting on Aliya Health Group is a public example: about 80 employees impacted across a corporate layoff of 40 and pending facility closures affecting another 37, under new CEO Frank Cid.
How should an operator sequence a residential facility closure to avoid enforcement exposure?
Model the decision, validate the licensure path with each state agency in writing, build the patient transition plan, and only then communicate publicly. For OTPs, SAMHSA’s Division of Pharmacologic Therapies requires notification through the online Form SMA-162 on the OTP Extranet, with a separate form for each change. DEA registration is surrendered by written notice with return of the original certificate. Announcing a closure before notifying the state licensing agency is the fastest way to turn a business decision into an enforcement matter.
How concentrated is private equity ownership in behavioral health right now?
The May 2024 JAMA Psychiatry study by Zhu, Greenberg, King, and Busch identified 642 mental health clinics and 1,152 addiction treatment clinics acquired by PE, or 6.2% of mental health facilities and 7.1% of addiction treatment facilities nationwide. In Colorado, Texas, and North Carolina, PE-owned practices accounted for roughly a quarter of facilities providing mental health treatment. The Private Equity Stakeholder Project separately tracked 1,049 PE-backed healthcare deals across all subsectors in 2024, with behavioral health among the noteworthy investment targets.
What federal enforcement risk should behavioral health operators be tracking in 2025 and 2026?
The FTC is the most active federal enforcer against deceptive behavioral health marketing and referral practices. On June 24, 2025, the FTC filed FTC v. Mercury Marketing, LLC et al. (1:25-cv-02021) in the U.S. District Court for the District of Maryland, naming eight corporate defendants including Aliya Health Group, LLC and four individuals, under Section 5 of the FTC Act, the Opioid Addiction Recovery Fraud Prevention Act, and the FTC’s Impersonation Rule. For a comparable outcome, the FTC’s separate June 2025 case against Evoke Wellness settled for $1.9 million in penalties, with the company barred from similar misconduct.
References
- Behavioral Health Business: Aliya Health Group Lays Off Staff, Will Close Locations Under New CEO (April 2026)
- FTC Press Release: FTC Sues to Stop Mercury Marketing and Others from Deceptively Advertising SUD Treatment Clinics (June 24, 2025)
- FTC Case Docket: Mercury Marketing LLC, FTC v. (D. Md. 1:25-cv-02021)
- Zhu JM, Greenberg E, King M, Busch S. Geographic Penetration of Private Equity Ownership in Outpatient and Residential Behavioral Health. JAMA Psychiatry. 2024;81(7):732–735.
- OHSU News: Study Finds Private Equity Expanding to Mental Health Facilities (May 2024)
- Private Equity Stakeholder Project: Private Equity Healthcare Deals: 2024 in Review
- Becker’s Behavioral Health: FTC Lawsuit Targets Deceptive SUD Marketing (June 2025)